tetano
Editor, Senior Moderator
Antimicrob Agents Chemother. 2010 Apr 5. [Epub ahead of print]
Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus Infection.
Sugaya N, Ohashi Y.
Department of Pediatrics, Keiyu Hospital, Yokohama, Japan; Department of Biostatistics, School of Public Health Science, University of Tokyo, Tokyo, Japan.
Abstract
We conducted a double-blind, randomized controlled trial to compare a long-acting neuraminidase inhibitor, laninamivir octanoate, with oseltamivir. Eligible patients were children 9 years of age and under who had febrile influenza symptoms of no more than 36 hours' duration. Patients were randomized to 1 of 3 treatment groups: a laninamivir 40 mg group (40-mg group), a laninamivir 20 mg group (20-mg group), or an oseltamivir group. Laninamivir octanoate was administered as a single inhalation. Oseltamivir 2 mg/kg was administered orally twice daily for 5 days. The primary endpoint was the time to alleviation of influenza illness. The primary analysis included 184 patients (61, 61, and 62 in the 40-mg group, 20-mg group, and oseltamivir group, respectively). Laninamivir octanoate markedly reduced the median time to illness alleviation in comparison with oseltamivir in patients infected with oseltamivir-resistant influenza A (H1N1), and the difference was -60.9 hours in the 40-mg group and -66.2 hours in the 20-mg group. On the other hand, there were no significant differences in the time to alleviation of illness between the laninamivir groups and oseltamivir group against influenza A (H3N2) or B infection. Laninamivir octanoate was well tolerated. The most common adverse events were gastrointestinal events. Laninamivir octanoate was an effective and well-tolerated treatment for children with oseltamivir-resistant influenza A (H1N1) virus infection. Further study will be needed to confirm clinical efficacy against influenza A (H3N2) or B virus infection. Its ease of administration is noteworthy, because a single inhalation is required during the course of illness.
PMID: 20368393 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20368393
Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus Infection.
Sugaya N, Ohashi Y.
Department of Pediatrics, Keiyu Hospital, Yokohama, Japan; Department of Biostatistics, School of Public Health Science, University of Tokyo, Tokyo, Japan.
Abstract
We conducted a double-blind, randomized controlled trial to compare a long-acting neuraminidase inhibitor, laninamivir octanoate, with oseltamivir. Eligible patients were children 9 years of age and under who had febrile influenza symptoms of no more than 36 hours' duration. Patients were randomized to 1 of 3 treatment groups: a laninamivir 40 mg group (40-mg group), a laninamivir 20 mg group (20-mg group), or an oseltamivir group. Laninamivir octanoate was administered as a single inhalation. Oseltamivir 2 mg/kg was administered orally twice daily for 5 days. The primary endpoint was the time to alleviation of influenza illness. The primary analysis included 184 patients (61, 61, and 62 in the 40-mg group, 20-mg group, and oseltamivir group, respectively). Laninamivir octanoate markedly reduced the median time to illness alleviation in comparison with oseltamivir in patients infected with oseltamivir-resistant influenza A (H1N1), and the difference was -60.9 hours in the 40-mg group and -66.2 hours in the 20-mg group. On the other hand, there were no significant differences in the time to alleviation of illness between the laninamivir groups and oseltamivir group against influenza A (H3N2) or B infection. Laninamivir octanoate was well tolerated. The most common adverse events were gastrointestinal events. Laninamivir octanoate was an effective and well-tolerated treatment for children with oseltamivir-resistant influenza A (H1N1) virus infection. Further study will be needed to confirm clinical efficacy against influenza A (H3N2) or B virus infection. Its ease of administration is noteworthy, because a single inhalation is required during the course of illness.
PMID: 20368393 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20368393
